Ostatní
Návod 
Nektar Therapeutics
NKTR
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
1.1B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
-142%
ROA
-40%
PE
-8
PS
16
Cena 1R
6-67
⌀ Cena
34.14
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
11-03-2026
Poslední dividenda
Profil
Biofarmaceutická společnost Nektar Therapeutics se zaměřuje na objevování a vývoj léčiv v oblastech nenaplněných léčebných potřeb ve Spojených státech a na mezinárodní úrovni. Mezi produkty společnosti patří Bempegaldesleukin, což je agonista metastazujícího melanomu CD122 (preferenční metastazující interleukin- 2) (IL- 2), který se nachází ve fázi 3 klinické studie k léčbě metastazujícího melanomu, karcinomu ledvin, karcinomu močového měchýře invazivního ve svalech, karcinomu hlavy a krku ze skvamózních buněk a adjuvantního melanomu; fáze 2 klinické studie k léčbě karcinomu ledvin, nemalobuněčného karcinomu plic a uroteliálního karcinomu; fáze 1/2A klinické studie k k k léčbě skvamózní buňky karcinomu hlavy fáze 1/2 klinického hodnocení léčby solidních nádorů a fáze 1B klinického hodnocení léčby COVID-19. Vyvíjí se také NKTR-358, stimulant cytokinového přípravku Treg, který je v klinické studii fáze 2 pro léčbu systémového lupus erythematodes a ulcerózní kolitidy, a dále klinická studie fáze 1B pro léčbu atopické dermatitidy a psoriázy; NKTR-255, agonista receptoru IL-15, který je v klinické studii fáze 1/2 pro léčbu nehodgkinského lymfomu a mnohočetného myelomu a karcinomu hlavy a krku a kolorektálního karcinomu; a NKTR-26 2, což je agonista receptorů podobný mýtnému, který je ve fázi 1/2 klinické studie k léčbě solidních nádorů, stejně jako různé jiné lékové kandidáty. Společnost má dohody o spolupráci se společností Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; a SFJ Pharmaceuticals, Inc. Nektar Therapeutics byla založena v roce 1990 a je se sídlem v San Franciscu v Kalifornii.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
61
Založení
1994-05-03
Podobné společnosti
$ 77.02
- $ 3.67
$ 4.37
+ $ 0.01
$ 15.95
+ $ 0.91
$ 12.37
+ $ 0.02
$ 6.24
+ $ 0.19
$ 14.19
+ $ 0.29
$ 9.14
+ $ 0.09
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 55.2 | 55.2 | 98.4 | 90.1 | 92.1 | 101.9 | 152.9 | 114.6 | 1,193.3 | 307.7 | 165.4 | 230.8 | 200.7 | 148.9 | 81.2 | 71.5 | 159.0 | |
| Cost of Revenues | 0.2 | 0.0 | 30.7 | 36.6 | 21.6 | 24.9 | 19.5 | 21.4 | 24.4 | 30.5 | 30.2 | 34.1 | 28.5 | 38.5 | 30.4 | 21.9 | 25.7 | |
| Gross Profit | 55.0 | 55.2 | 67.7 | 53.5 | 70.4 | 77.0 | 133.4 | 93.2 | 1,168.9 | 277.2 | 135.2 | 196.7 | 172.2 | 110.4 | 50.8 | 49.6 | 133.4 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 21.8 | 11.8 | 11.2 | 10.5 | 29.2 | 24.1 | 23.5 | 21.6 | 23.9 | 24.1 | |
| Cost of Revenues | 0.0 | 0.2 | 0.0 | 0.0 | 8.0 | 4.4 | 9.7 | 8.5 | 7.3 | 12.4 | |
| Gross Profit | 21.8 | 11.6 | 11.2 | 10.5 | 21.2 | 19.7 | 13.7 | 13.1 | 16.6 | 11.7 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 114.2 | 218.3 | 400.3 | 408.7 | 434.6 | 399.5 | 268.5 | 203.8 | 182.8 | 147.7 | 190.0 | 148.7 | 126.8 | 108.1 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 77.4 | 92.3 | 122.8 | 104.7 | 98.7 | 81.4 | 52.4 | 44.3 | 43.3 | 40.9 | 40.5 | 41.6 | 46.8 | 41.0 | |
| Depreciation & Amortization | 1.0 | 1.0 | 4.4 | 7.8 | 19.7 | -7.7 | 32.5 | 59.5 | 10.9 | 14.7 | 15.4 | 12.9 | 12.9 | 14.3 | 14.5 | 15.0 | 16.6 | |
| Total Operating Expenses | 186.4 | 186.0 | 172.9 | 190.9 | 310.7 | 523.1 | 513.4 | 533.3 | 481.0 | 320.8 | 248.1 | 226.1 | 188.7 | 230.5 | 190.3 | 173.5 | 149.1 | |
| Operating Income | -131.4 | -130.8 | -105.2 | -137.4 | -240.2 | -446.1 | -379.9 | -440.0 | 687.9 | -59.6 | -112.9 | -29.4 | -16.5 | -120.1 | -141.2 | -123.9 | -28.3 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 29.9 | 24.1 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 17.3 | 21.1 | ||
| Depreciation & Amortization | 0.2 | 0.2 | 0.2 | 0.4 | 0.3 | 1.0 | 1.5 | 1.6 | 1.7 | 1.7 | ||
| Total Operating Expenses | 40.9 | 43.1 | 47.4 | 55.0 | 6.9 | 54.0 | 63.5 | 48.5 | 47.3 | 45.2 | ||
| Operating Income | -19.1 | -31.5 | -36.2 | -44.5 | 14.3 | -34.3 | -49.8 | -35.4 | -30.7 | -44.9 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 10.4 | 10.4 | 14.5 | 19.0 | 6.7 | 2.6 | 18.3 | 46.3 | 37.6 | 4.5 | 2.4 | 1.7 | 0.8 | 0.7 | 2.3 | 2.2 | 1.5 | |
| Interest Expense | 26.2 | 26.2 | 28.1 | 25.3 | 28.9 | 47.3 | 37.1 | 46.4 | 42.8 | 41.0 | 42.2 | 38.9 | 38.8 | 40.8 | 33.5 | 10.2 | 11.2 | |
| Other Expense | -32.8 | -33.4 | -14.0 | -138.8 | -124.7 | -77.2 | -64.0 | 0.0 | -5.2 | -16.0 | -39.8 | -14.1 | -37.9 | 0.4 | -0.7 | -1.0 | -11.7 | |
| IBT | -164.2 | -164.2 | -119.2 | -276.3 | -365.0 | -523.3 | -443.9 | -440.1 | 682.7 | -96.1 | -152.6 | -80.7 | -54.4 | -159.8 | -171.4 | -133.0 | -37.1 | |
| Income Tax Expense | -0.1 | -0.1 | -0.2 | -0.2 | 3.2 | 0.6 | 0.5 | 0.6 | 1.4 | 0.6 | 0.9 | 0.5 | -0.5 | 2.2 | 0.4 | 1.0 | 0.9 | |
| Net Income | -164.1 | -164.1 | -119.0 | -276.1 | -368.2 | -523.8 | -444.4 | -440.7 | 681.3 | -96.7 | -153.5 | -81.2 | -53.9 | -162.0 | -171.9 | -134.0 | -37.9 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 2.8 | 2.8 | 2.0 | 2.9 | 2.9 | 3.4 | 3.9 | 4.2 | 4.6 | 4.9 | ||
| Interest Expense | 9.8 | 6.0 | 5.4 | 5.0 | 10.2 | 6.0 | 6.4 | 5.5 | 6.9 | 5.9 | ||
| Other Expense | -17.0 | -4.0 | -5.6 | -6.3 | -7.3 | -2.7 | -2.5 | -1.4 | -8.6 | -1.0 | ||
| IBT | -36.0 | -35.6 | -41.8 | -50.8 | 7.0 | -37.0 | -52.3 | -36.8 | -42.1 | -45.9 | ||
| Income Tax Expense | 0.0 | 0.0 | -0.2 | 0.1 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | ||
| Net Income | -36.1 | -35.5 | -41.6 | -50.9 | 7.3 | -37.1 | -52.4 | -36.8 | -42.1 | -45.8 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | $-0.61 | $-0.42 | $-1.40 | $-1.50 | $-1.19 | $-0.40 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | $-0.61 | $-0.42 | $-1.40 | $-1.50 | $-1.19 | $-0.40 | |
| Shares Outstanding | 20.3 | 16.9 | 13.7 | 190.0 | 187.1 | 183.3 | 178.6 | 175.0 | 180.1 | 156.0 | 139.6 | 132.5 | 126.9 | 115.7 | 114.8 | 112.9 | 94.1 | |
| Diluted Shares Outstanding | 20.3 | 16.9 | 13.7 | 190.0 | 187.1 | 183.3 | 178.6 | 175.0 | 180.1 | 156.0 | 139.6 | 132.5 | 126.9 | 115.7 | 114.8 | 112.9 | 94.1 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.22 | $-0.24 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.22 | $-0.24 | ||
| Shares Outstanding | 20.3 | 14.1 | 14.1 | 14.1 | 14.0 | 13.9 | 13.9 | 13.0 | 191.0 | 190.4 | ||
| Diluted Shares Outstanding | 20.3 | 14.1 | 14.1 | 14.1 | 14.2 | 13.9 | 13.9 | 13.0 | 191.0 | 190.4 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 13.9 | 44.3 | 35.3 | 88.2 | 25.2 | 199.0 | 96.4 | 194.9 | 4.8 | 59.6 | 55.6 | 12.4 | 39.1 | 25.4 | 15.3 | 17.8 | |
| Short Term Investments | 257.3 | 211.0 | 268.3 | 416.8 | 708.7 | 862.9 | 1,228.5 | 1,140.4 | 291.4 | 329.5 | 253.4 | 225.5 | 198.0 | 251.8 | 225.9 | 298.2 | |
| Total Cash & ST Investments | 271.2 | 255.2 | 303.6 | 505.0 | 734.0 | 1,061.9 | 1,324.9 | 1,335.4 | 296.1 | 389.1 | 308.9 | 237.8 | 237.0 | 277.2 | 241.2 | 315.9 | |
| Accounts Receivable | 2.9 | 1.6 | 2.3 | 6.0 | 22.5 | 38.9 | 36.8 | 43.2 | 5.0 | 15.7 | 19.9 | 3.6 | 2.2 | 5.8 | 4.9 | 25.1 | |
| Inventory | 14.5 | 0.0 | 16.1 | 19.2 | 15.8 | 15.3 | 12.7 | 11.4 | 10.7 | 11.1 | 11.3 | 13.0 | 13.5 | 18.3 | 12.7 | 7.3 | |
| Other Current Assets | 6.6 | 4.5 | 8.7 | 15.8 | 23.3 | 18.0 | 15.4 | 21.3 | 14.9 | 10.4 | 9.8 | 8.8 | 5.2 | 13.4 | 17.9 | 5.7 | |
| Total Current Assets | 295.2 | 261.3 | 330.7 | 546.0 | 795.6 | 1,138.0 | 1,421.6 | 1,437.7 | 326.8 | 426.3 | 350.1 | 288.2 | 257.9 | 314.6 | 276.7 | 354.0 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 41.0 | 43.0 | 38.9 | 44.3 | 30.1 | 13.9 | 48.6 | 20.2 | 64.9 | 50.7 | |
| Short Term Investments | 229.2 | 132.9 | 179.7 | 211.0 | 214.4 | 257.3 | 240.6 | 283.5 | 307.7 | 358.7 | |
| Total Cash & ST Investments | 270.2 | 175.9 | 218.6 | 255.2 | 244.5 | 271.2 | 289.2 | 303.6 | 372.7 | 409.4 | |
| Accounts Receivable | 1.3 | 1.4 | 1.7 | 1.6 | 2.1 | 2.9 | 5.4 | 2.3 | 2.2 | 1.3 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.5 | 16.2 | 16.1 | 15.1 | 20.7 | |
| Other Current Assets | 9.9 | 9.3 | 9.6 | 4.5 | 39.9 | 6.6 | 8.9 | 8.7 | 9.0 | 9.6 | |
| Total Current Assets | 281.4 | 186.6 | 229.9 | 261.3 | 286.5 | 295.2 | 319.8 | 330.7 | 399.0 | 441.1 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 24.4 | 11.8 | 36.9 | 85.9 | 177.5 | 186.1 | 199.2 | 48.9 | 47.5 | 65.6 | 71.3 | 70.4 | 67.0 | 72.2 | 78.6 | 89.8 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | 76.5 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 19.4 | 26.1 | 25.8 | 0.0 | 64.8 | 136.7 | 279.1 | 582.9 | 57.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 173.8 | 0.0 | |
| Other Long-Term Assets | 4.3 | 4.6 | 4.6 | 2.2 | 2.7 | 1.5 | 1.0 | 4.2 | 1.0 | 0.5 | 4.2 | 6.6 | 33.2 | 34.4 | 1.0 | 1.0 | |
| Total Long-Term Assets | 48.1 | 42.6 | 67.3 | 164.6 | 321.6 | 400.8 | 555.8 | 712.5 | 182.0 | 142.6 | 152.0 | 153.4 | 176.6 | 183.2 | 329.8 | 167.2 | |
| Total Assets | 343.3 | 303.9 | 398.0 | 710.6 | 1,117.2 | 1,538.8 | 1,977.4 | 2,150.2 | 508.9 | 568.9 | 502.1 | 441.6 | 434.5 | 497.8 | 606.6 | 521.2 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 10.0 | 10.6 | 11.2 | 11.8 | 12.4 | 24.4 | 34.7 | 36.9 | 38.7 | 51.6 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 4.8 | 5.4 | 9.8 | 26.1 | 4.5 | 19.4 | 36.8 | 25.8 | 0.0 | 0.0 | |
| Other Long-Term Assets | 5.2 | 5.0 | 5.4 | 4.6 | 4.5 | 4.3 | 4.7 | 4.6 | 4.5 | 1.7 | |
| Total Long-Term Assets | 20.0 | 21.0 | 26.3 | 42.6 | 21.5 | 48.1 | 76.2 | 67.3 | 43.2 | 53.2 | |
| Total Assets | 301.3 | 207.5 | 256.2 | 303.9 | 308.0 | 343.3 | 396.0 | 398.0 | 442.2 | 494.3 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 6.5 | 11.6 | 9.8 | 13.0 | 9.7 | 22.1 | 19.2 | 5.9 | 4.8 | 2.8 | 2.4 | 2.7 | 9.1 | 2.9 | 3.0 | 7.2 | |
| Short-Term Debt | 21.3 | 19.9 | 38.5 | 18.7 | 17.4 | 13.9 | 261.2 | 61.8 | 32.0 | 2.9 | 4.8 | 4.5 | 44.3 | 41.4 | 215.0 | 29.9 | |
| Other Current Liabilities | 29.5 | 30.0 | 2.9 | 36.6 | 58.0 | 79.6 | 67.9 | 0.5 | 0.4 | 52.1 | 32.7 | 32.4 | 21.1 | 12.4 | 37.9 | 6.4 | |
| Current Liabilities | 57.3 | 61.4 | 51.3 | 68.2 | 85.2 | 115.8 | 353.9 | 82.0 | 56.2 | 72.2 | 61.2 | 64.0 | 98.2 | 78.5 | 275.5 | 64.1 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 15.6 | 14.3 | 17.8 | 11.6 | 8.6 | 6.5 | 8.8 | 9.8 | 3.3 | 2.6 | |
| Short-Term Debt | 22.2 | 22.0 | 21.8 | 19.9 | 21.5 | 21.3 | 19.4 | 38.5 | 38.2 | 37.9 | |
| Other Current Liabilities | 28.6 | 35.1 | 31.3 | 30.0 | 37.5 | 29.5 | 24.3 | 2.9 | 10.6 | 10.2 | |
| Current Liabilities | 66.3 | 71.4 | 70.9 | 61.4 | 67.6 | 57.3 | 52.4 | 51.3 | 52.1 | 50.7 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 107.5 | 82.7 | 98.5 | 112.8 | 125.7 | 136.4 | 142.7 | 247.0 | 245.2 | 245.7 | 243.2 | 129.1 | 133.0 | 136.6 | 14.6 | 232.0 | |
| Capital Leases | 90.8 | 102.6 | 117.8 | 131.5 | 143.2 | 150.3 | 155.2 | 0.0 | 0.0 | 5.1 | 5.8 | 8.7 | 8.0 | 11.6 | 14.6 | 17.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 263.6 | 243.1 | 267.0 | 344.0 | 437.7 | 461.5 | 572.0 | 432.6 | 421.0 | 480.7 | 495.6 | 405.3 | 524.4 | 450.8 | 408.7 | 430.6 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 69.7 | 74.1 | 78.5 | 82.7 | 86.8 | 198.3 | 94.7 | 98.5 | 102.2 | 105.8 | |
| Capital Leases | 91.9 | 96.2 | 100.3 | 102.6 | 108.3 | 90.8 | 114.1 | 98.5 | 121.3 | 124.8 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 216.3 | 231.7 | 242.5 | 243.1 | 259.1 | 263.6 | 269.3 | 267.0 | 282.9 | 297.3 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -3,566.4 | -3,596.2 | -3,477.2 | -3,201.2 | -2,833.0 | -2,309.2 | -1,864.7 | -1,424.1 | -2,117.9 | -2,021.0 | -1,867.5 | -1,786.3 | -1,732.4 | -1,570.4 | -1,398.5 | -1,264.5 | |
| Comprehensive Income | -0.5 | 0.1 | 0.1 | -6.9 | -4.2 | -2.3 | -1.0 | -6.3 | -2.1 | -2.4 | -2.2 | -1.6 | -1.2 | -0.4 | -1.1 | 1.0 | |
| Total Common Equity | 79.7 | 60.7 | 131.0 | 366.6 | 679.5 | 1,077.3 | 1,405.4 | 1,717.6 | 87.8 | 88.1 | 6.4 | 36.3 | -89.9 | 47.0 | 197.8 | 90.7 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -3,724.2 | -3,688.7 | -3,647.1 | -3,596.2 | -3,603.5 | -3,566.4 | -3,514.1 | -3,477.2 | -3,435.2 | -3,389.3 | |
| Comprehensive Income | 0.1 | 0.0 | 0.0 | 0.1 | 0.4 | -0.5 | -0.4 | 0.1 | -6.4 | -6.5 | |
| Total Common Equity | 85.1 | -24.2 | 13.7 | 60.7 | 48.9 | 79.7 | 126.7 | 131.0 | 159.4 | 197.0 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 219.6 | 102.6 | 230.4 | 131.5 | 143.2 | 150.3 | 403.9 | 247.0 | 245.2 | 248.6 | 247.9 | 133.7 | 133.0 | 136.6 | 229.5 | 232.0 | |
| Book Value | 79.7 | 60.7 | 131.0 | 366.6 | 679.5 | 1,077.3 | 1,405.4 | 1,717.6 | 87.8 | 88.1 | 6.4 | 36.3 | -89.9 | 47.0 | 197.8 | 90.7 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 85.1 | -24.2 | 13.7 | 60.7 | 48.9 | 79.7 | 126.7 | 131.0 | 159.4 | 197.0 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -177.1 | -164.1 | -119.0 | -276.1 | -368.2 | -523.8 | -444.4 | -440.7 | 681.3 | -96.7 | -153.5 | -81.2 | -53.9 | -162.0 | -171.9 | -134.0 | -37.9 | |
| Depreciation & Amortization | 6.4 | -4.5 | 4.4 | 7.8 | 13.0 | 14.1 | 14.2 | 13.2 | 10.9 | 14.7 | 15.4 | 12.9 | 12.9 | 14.3 | 14.5 | 15.0 | 16.6 | |
| Stock-Based Compensation | 26.8 | 12.6 | 21.6 | 33.4 | 57.3 | 94.7 | 94.3 | 99.8 | 88.1 | 36.6 | 25.9 | 19.7 | 17.0 | 17.7 | 16.2 | 18.9 | 17.4 | |
| Change Working Capital | -5.0 | -37.0 | -6.2 | -19.8 | 0.5 | -23.1 | 16.7 | 21.7 | -39.0 | -37.6 | 7.9 | -34.7 | -116.4 | 90.6 | 1.6 | -15.0 | -64.7 | |
| Change In Accounts Receivable | 0.1 | 0.0 | -3.0 | 4.8 | 16.5 | 12.4 | 1.9 | 6.4 | -25.5 | 10.7 | 4.3 | -16.3 | -1.4 | 3.6 | -0.9 | 20.2 | -20.3 | |
| Change In Accounts Payable | 3.8 | -0.6 | 2.7 | -2.9 | 3.1 | -11.7 | 2.4 | 13.0 | 1.0 | 2.1 | 0.5 | -0.4 | -6.4 | 6.2 | -0.1 | -3.4 | 4.3 | |
| Change In Inventories | 1.3 | 0.0 | 0.5 | 0.7 | -3.4 | -0.5 | -2.6 | -1.3 | -0.7 | 0.4 | 0.2 | 1.6 | 0.5 | 4.8 | -5.6 | -5.4 | -0.8 | |
| Other Non-cash Items | -5.9 | -15.6 | -76.5 | 62.2 | -9.4 | 17.4 | -14.4 | -22.7 | -23.1 | -12.5 | -12.6 | 8.7 | -1.6 | 0.9 | 8.1 | -132.6 | 0.2 | |
| Cash from Operations | -174.8 | 0.0 | 0.0 | -192.6 | -304.0 | -412.7 | -313.3 | -328.7 | 718.2 | -80.4 | -117.0 | -73.1 | -142.0 | -38.5 | -129.8 | -113.7 | -55.9 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -36.1 | -35.5 | -41.6 | -50.9 | 7.3 | -37.1 | -52.4 | -36.8 | -42.1 | -45.8 | |
| Depreciation & Amortization | -0.4 | 0.2 | -0.7 | 0.4 | 0.3 | 1.0 | 1.5 | 1.6 | 1.7 | 1.7 | |
| Stock-Based Compensation | 2.2 | 3.1 | 3.5 | 3.9 | 4.8 | 0.0 | 5.4 | 0.0 | 7.3 | 8.1 | |
| Change Working Capital | -23.1 | -10.2 | -3.6 | -0.1 | -11.5 | 1.1 | 10.8 | -6.6 | -4.7 | -4.5 | |
| Change In Accounts Receivable | 0.0 | 0.0 | 0.0 | 0.0 | -2.2 | -0.9 | 2.4 | -2.4 | 1.0 | -0.9 | |
| Change In Accounts Payable | -4.8 | 1.3 | -3.5 | 6.4 | 3.7 | 2.2 | -2.3 | -1.0 | 6.4 | 0.7 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 0.1 | 0.2 | -1.1 | 1.1 | 1.1 | |
| Other Non-cash Items | -7.6 | -6.3 | -3.4 | -2.3 | -47.1 | -8.9 | -3.1 | -6.0 | -10.9 | -1.6 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -47.0 | -42.1 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.6 | -0.2 | -1.5 | -0.9 | -5.7 | -15.0 | -7.3 | -26.3 | -14.2 | -9.7 | -6.4 | -11.2 | -10.0 | -4.1 | -10.6 | -9.7 | -31.5 | |
| Acquisitions | 66.4 | -0.7 | 65.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -435.5 | -285.0 | -261.7 | -511.7 | -467.9 | -960.7 | -987.5 | -1,380.9 | -2,271.3 | -404.4 | -334.7 | -297.6 | -297.3 | -268.1 | -164.7 | -695.4 | -443.1 | |
| Sales of Investment | 544.9 | 284.7 | 340.4 | 650.9 | 826.2 | 1,178.5 | 1,491.0 | 1,614.0 | 902.9 | 385.3 | 258.7 | 269.5 | 269.7 | 322.1 | 313.3 | 593.1 | 491.3 | |
| Other Investing Activities | -65.1 | 0.0 | 0.0 | 1.2 | 13.2 | 0.0 | 0.0 | 0.0 | 2.6 | 0.0 | 0.0 | 25.0 | 0.0 | 0.0 | -25.0 | 0.0 | 0.0 | |
| Cash from Investing | 110.0 | 0.0 | 0.0 | 139.6 | 365.8 | 202.8 | 496.2 | 206.9 | -1,379.9 | -28.8 | -82.4 | -14.3 | -37.6 | 49.9 | 113.0 | -112.0 | 16.7 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.0 | -0.1 | 0.0 | 0.0 | -0.5 | -0.7 | -0.2 | -0.2 | -0.2 | 0.0 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 65.1 | 1.2 | |
| Investments | -91.6 | -149.6 | -18.9 | -24.9 | -69.8 | -18.4 | -68.4 | -105.1 | -138.9 | -123.1 | |
| Sales of Investment | 92.0 | 54.8 | 68.6 | 69.3 | 65.1 | 65.2 | 85.6 | 124.5 | 156.5 | 178.3 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -65.1 | 0.0 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 17.4 | 56.4 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -15.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -250.0 | 0.0 | 0.0 | -5.1 | -5.9 | -142.7 | -3.5 | -3.0 | -174.8 | -2.0 | -1.4 | |
| Debt Issued | 109.9 | 102.6 | -127.8 | 98.9 | -11.7 | -7.1 | -3.7 | 157.0 | 1.7 | 1.7 | 6.6 | 257.0 | 4.1 | -0.6 | 81.9 | -0.5 | 233.3 | |
| Issuance of Common Stock | 30.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 790.2 | 59.5 | 189.3 | 32.2 | 116.5 | 8.2 | 0.0 | 224.3 | 8.9 | |
| Repurchase of Common Stock | -3.0 | 0.0 | -3.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 80.0 | 0.0 | 0.0 | 0.0 | 1.5 | 36.2 | 169.6 | 23.4 | 61.7 | 0.0 | 20.3 | 241.3 | 40.0 | -3.0 | 201.6 | 0.0 | 0.0 | |
| Cash from Financing | -22.9 | 0.0 | 0.0 | 0.0 | 1.5 | 36.2 | -80.4 | 23.4 | 852.0 | 54.4 | 203.6 | 130.8 | 153.0 | 2.2 | 26.8 | 222.3 | 7.5 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 91.9 | -4.2 | -4.2 | -2.2 | -5.7 | -111.3 | 105.5 | -116.3 | 109.1 | -3.5 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -64.9 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -29.3 | -29.1 | 9.0 | -53.0 | 63.0 | -173.7 | 102.6 | -98.5 | 190.1 | -54.9 | 4.1 | 43.2 | -26.7 | 13.6 | 10.1 | -2.4 | -31.8 | |
| Closing Cash Balance | 13.9 | 15.1 | 44.3 | 35.3 | 88.2 | 25.2 | 199.0 | 96.4 | 194.9 | 4.8 | 59.6 | 55.6 | 12.4 | 39.1 | 25.4 | 15.3 | 17.8 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -1.2 | -2.0 | 4.1 | -5.4 | 14.1 | 2.1 | -20.8 | 14.6 | -29.6 | 6.5 | |
| Closing Cash Balance | 15.1 | 41.0 | 43.0 | 38.9 | 44.3 | 16.1 | 13.9 | 34.7 | 20.2 | 49.7 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -175.4 | -208.7 | -177.2 | -193.5 | -309.7 | -427.6 | -320.5 | -355.0 | 704.0 | -90.1 | -123.4 | -84.3 | -152.0 | -42.6 | -140.3 | -123.5 | -87.3 | |
| Real Free Cash Flow | -202.2 | -221.3 | -198.8 | -226.9 | -367.0 | -522.3 | -414.8 | -454.8 | 615.9 | -126.7 | -149.3 | -103.9 | -169.0 | -60.3 | -156.5 | -142.3 | -104.7 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -65.0 | -48.9 | -45.8 | -49.1 | -46.6 | -44.6 | -37.9 | -48.0 | -47.3 | -42.2 | |
| Real Free Cash Flow | -67.2 | -51.9 | -49.3 | -53.0 | -51.4 | -44.6 | -43.3 | -48.0 | -54.5 | -50.3 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -8.3 | -138.2 | -1.4 |
| P/S | 16 | 130.5 | 9.4 |
| P/B | 11.8 | -1085.2 | 5.2 |
| P/FCF | -4.9 | -134.2 | -1.5 |
| Market cap | $1.1 | $1.2 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 30.5 % | 31.2 % | 0 % |
| Debt to Income | -56 % | -201.9 % | 0 % |
| Debt to Free cash flow | -41.5 % | -110.1 % | 0 % |
| Interest expense percentage | -19.9 % | -36.2 % | 44.7 % |
| Current ratio | 4.2 | 6.1 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -192.8 % | 756.6 % | 0 % |
| ROA | -54.4 % | -27.5 % | 0 % |
| CapEx to Revenue | 1 % | 8.1 % | 0 % |
| RaD to Revenue | 0 % | 163.9 % | 0 % |
| ROEM | 905,442.6 | 482891.6 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 87.3 % | 79.2 % | 68.7 % |
| Operating margin | -156.7 % | -145.5 % | 35.5 % |
| Net margin | -192.9 % | -181.1 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 14.1 mil | 148.3 mil |
| Employee count | 0.1 tis | 0.5 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
